Prestige Consumer Healthcare Inc (NYSE:PBH)
| 58.39 Delayed Data As of 3:59pm ET |  +0.47 / +0.81%Today’s Change | 48.51 Today|||52-Week Range 68.54 | -6.73% Year-to-Date |
Latest PBH News | Press Releases
| Why Prestige Consumer Healthcare (PBH) is a Top Value Stock for the Long-Term Sep 22 / Zacks.com - Paid Partner Content | PBH vs. BSX: Which Stock Is the Better Value Option? Sep 14 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 57.92 |
| Today’s open | 57.89 |
| Day’s range | 57.89 - 58.96 |
| Volume | 157,979 |
| Average volume (3 months) | 240,426 |
| Market cap | $2.9B |
Data as of 3:59pm ET, 09/25/2023
Growth & Valuation
| Earnings growth (last year) | -140.37% |
| Earnings growth (this year) | +2.26% |
| Earnings growth (next 5 years) | +8.50% |
| Revenue growth (last year) | +3.76% |
| P/E ratio | NM |
| Price/Sales | 2.77 |
| Price/Book | 1.99 |
Competitors
| ---- | ||
| MDGLMadrigal Pharmaceuti... | -2.63 | -1.72% |
| MRTXMirati Therapeutics ... | +0.30 | +0.73% |
| CYTKCytokinetics Inc | -0.97 | -3.13% |
Data as of 4:00pm ET, 09/25/2023
Financials
| Next reporting date | November 2, 2023 |
| EPS forecast (this quarter) | $1.09 |
| Annual revenue (last year) | $1.1B |
| Annual profit (last year) | -$82.3M |
| Net profit margin | -7.30% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Tarrytown, New York |
Forecasts
